ANGEL MATHEW: Open Payments
NPI 1487284261 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$508 in 19 payments from 11 companies in 2025. Trend: 2023 $372 · 2024 $695 · 2025 $508
Food & beverage: $508
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $171 |
| ABBVIE INC. | 4 | $74 |
| Legend Biotech USA Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| GENZYME CORPORATION | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| SOBI, INC | 1 | $17 |
Products named: CALQUENCE, CARVYKTI, Vanflyta, Fabhalta, EPKINLY, VENCLEXTA, PYRUKYND, Polivy.
Industry payments across TX — which companies pay providers there.
